# Aavatar Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aavatar-therapeutics

- Industry: Biotechnology
- Headquarters: Hanam, South Korea
- Website: https://www.aavatartps.com/
- Total disclosed funding: $7.4M
- Latest round: Series B (Sep 29, 2026)
- Investors on record: 5

## About

Founded in 2020 and based in Gyeonggi-do, South Korea, Aavatar Therapeutics Inc. operates as a biotechnology company that develops nanoparticle-based products as agents to treat genetic diseases. As of November 2023, the company is being led by its CEO, Seunghee Cho. In September 2026, Aavatar Therapeutics Inc. raised KRW 5 billion in series B funding from HB Investment. The round was part of a larger KRW 25 billion series B funding.

The firm develops and offers a gene therapy platform based on artificial intelligence (AI) and deep learning that provides individual diagnoses based on their disease and offers gene therapy products created using nanoparticles to offer therapies. The company creates drugs using capsid engineering and promoter engineering technologies. 

he company will use the funding to further develop its AAV-based gene therapy platform. HB Investment backed the company based on its next-generation capsid engineering technology and experienced gene therapy development team.

## Funding rounds

- Series B, Sep 29, 2026, $3.6M — HB Investment
- Series A, Nov 7, 2023, $3.8M — Smilegate Investment, Shinhan Capital, WONIK Investment Partners, T.S. Investment

## Investors

- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A
- Shinhan Capital (https://capitalatlas.ai/funds/shinhan-capital) — Series A
- WONIK Investment Partners (https://capitalatlas.ai/funds/wonik-investment-partners) — Series A
- T.S. Investment (https://capitalatlas.ai/funds/t-s-investment) — Series A
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series B